You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
DARPA program managers said they are developing different testing modalities that are crucially linked in their objective to facilitate more comprehensive and faster testing.
The firm said its test detects biomarkers inside monocyte blood cells that reflect the reduced clearance of amyloid-beta plaque that leads to Alzheimer's disease.
The firm said it is developing a rapid test for chlamydia and gonorrhea that will be able to detect multiple infections in the same sample in around 15 minutes.
The company said the study will evaluate the ability of its Reveal System to detect and characterize antimicrobial resistance of Gram-negative bacteremia samples.
Molzym said a new analytic platform, called AutoSepT, would enable fast pathogen identification directly from specimens in less than five hours.
Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.
A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.
The group is developing an ultrasensitive nanoparticle-enhanced plasmonic biosensor to detect RAS single nucleotide variants in plasma.
The funding is part of a BARDA contract worth up to $72 million to support the development of a test to diagnose acute infection at the point of care.
The test detects intact particles by connecting single-stranded DNA with fluorophores to the virus, enabling the detection of a single viral particle.